1. Scrip
  2. >>Business
  3. >>Financing

Tango Bypasses IPO Route With SPAC Merger

Cancer Firm Will Raise $353m, List On US Stock Market In Q3

 
• By Mandy Jackson

The cancer drug developer was planning to go public later this year, but its series B investor Boxer Capital proposed a merger with its special purpose acquisition corporation, BCTG Acquisition.

SPAC vs IPO blocks
Tango did not consider a SPAC merger until its investor Boxer Capital suggested a deal • Source: Alamy

Tango Therapeutics, Inc. will bring its cash balance to $553m later this year and become a publicly traded company in the US when it closes a merger with the special purpose acquisition corporation (SPAC) known as BCTG Acquisition Corp., which was sponsored by frequent biopharmaceutical company investor Boxer Capital. Tango will raise $353m through the deal announced on 14 April, including $167m held in trust by BCTG and $186m from a concurrent private investment in public equity (PIPE) financings.

SPACs, also known as blank check companies, launch initial public offerings to raise money that facilitates a merger with another...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Financing

Finance Watch: Ever The Outlier, Biotech Outpaces Broader Stocks

 
• By Mandy Jackson

Public Company Edition: The US jobs report for August hurt the S&P 500 and Dow Jones, but the XBI rose 2.2% and is up 6% year-to-date. Despite signs of life, with a recent small IPO from Curanex and a larger one proposed by LB Pharmaceuticals, fundraising was down in Q2.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Finance Watch: Treeline Emerges From The Shadows With $200m, Bringing Total To $1.1bn

 
• By Mandy Jackson

Private Company Edition: Treeline will fund Phase I trials for at least four cancer drugs with its $200m series A extension. Also, allogeneic CAR-T developer Wugen raised $115m, CHARM Therapeutics garnered $80m in series B cash and Plexium disclosed a $60.1m financing.

Mineralys In The Money As Lorundrostat Gets Close To Market

 
• By Kevin Grogan

An upsized public offering will add $250m to the company’s coffers.

More from Business

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data

 
• By Jessica Merrill

R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.